# Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens

> **NCT02625155** · PHASE4 · UNKNOWN · sponsor: **InSource Diagnostics** · enrollment: 14000 (estimated)

## Conditions studied

- Target Drug-related Adverse Events

## Interventions

- **OTHER:** Urine diagnostic testing as SOC, drug regimen changes per SOC
- **OTHER:** Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results

## Key facts

- **NCT ID:** NCT02625155
- **Lead sponsor:** InSource Diagnostics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12
- **Primary completion:** 2018-12
- **Final completion:** —
- **Target enrollment:** 14000 (ESTIMATED)
- **Last updated:** 2018-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02625155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02625155, "Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02625155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*